Rani Therapeutics Holdings, Inc. 8-K

What Happened

• Rani Therapeutics Holdings, Inc. (RANI) announced it entered into a securities purchase agreement with institutional investors to sell 12,476,637 shares of Class A common stock and pre-funded warrants to purchase 6,214,953 additional shares. The offering prices are $1.07 per share and $1.0699 per pre-funded warrant. Gross proceeds are expected to be approximately $20.0 million before placement agent fees and offering expenses. The closing was expected on or about May 27, 2026.
• The pre-funded warrants are exercisable immediately, have an exercise price of $0.0001 per share, and remain exercisable until fully exercised. Rani engaged H.C. Wainwright & Co., LLC (lead placement agent) and Chardan Capital Markets LLC as placement agent and agreed to pay a cash fee equal to 6.0% of the aggregate gross proceeds plus certain expense reimbursements.

Key Details

• Securities sold: 12,476,637 Class A common shares; pre-funded warrants to purchase 6,214,953 shares.
• Prices: $1.07 per share; $1.0699 per pre-funded warrant. Aggregate gross proceeds: ~ $20.0 million (pre-fees/expenses).
• Pre-funded warrant terms: exercisable immediately; $0.0001 exercise price. If all pre-funded warrants are exercised, up to 18,691,590 total shares would be issued in connection with the offering.
• Restrictions: company agreed not to issue or announce new shares or common-equivalent securities for 90 days (with customary exceptions) and not to enter new variable-rate transactions for nine months; certain insiders agreed to 60-day lock-ups. Offering is being made under Rani’s Form S-3 registration statement.

Why It Matters

• The offering provides Rani with near-term cash (about $20M gross) to support operations, but will dilute existing shareholders because new shares are being issued and pre-funded warrants may be exercised into additional shares.
• Placement agent fees (6%) and offering costs will reduce net proceeds. Lock-up and issuance restrictions temporarily limit the company’s ability to raise additional equity or enter certain financing transactions, which can affect short-term financing flexibility.
• Investors should note the low exercise price of the pre-funded warrants ($0.0001) and that they are exercisable immediately, meaning additional share dilution could occur quickly if exercised.